Review: Rapid-acting analogues do not differ from regular human insulin for mortality or HbA1c in type 2 diabetes.

Davidson MB. Review: Rapid-acting analogues do not differ from regular human insulin for mortality or HbA1c in type 2 diabetes. Ann Intern Med. 2019 04 16; 170(8):JC39.

View in: PubMed

subject areas

Adult
Diabetes Mellitus, Type 2
Humans
Hypoglycemic Agents
Insulin

authors with profiles

Mayer B. Davidson, MD

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support